T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica.
Giulia CeglieLaura PapettiLorenzo Figà TalamancaBarbarella LucarelliMattia AlgeriStefania GaspariGiuseppina Li PiraGiovanna-Stefania ColafatiMauro MontanariMassimiliano ValerianiFranco LocatelliPietro MerliPublished in: Annals of clinical and translational neurology (2019)
Neuromyelitis optica is an immune-mediated disease characterized by a relapsing course, resulting in progressive disability. In children, given the long life expectancy, a disease-modifying treatment could be particularly desirable. Unfortunately, the currently available treatment strategies with this potential are scarce. Very limited data are available about the use of allogeneic hematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases. In this report, we present a pediatric case successfully treated with allogeneic HSCT from an HLA-haploidentical donor, after ex vivo TCR/CD19-depletion of the graft. To the best of our knowledge, this is the first case of a pediatric patient to benefit from such a treatment.
Keyphrases
- multiple sclerosis
- stem cell transplantation
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- hematopoietic stem cell
- healthcare
- acute myeloid leukemia
- acute lymphoblastic leukemia
- peripheral blood
- young adults
- regulatory t cells
- rheumatoid arthritis
- machine learning
- low dose
- drug induced
- high dose
- cord blood
- childhood cancer